Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2018-08-31 6-K ASTRAZENECA UPDATE ON ANIFROLUMAB IN SLE View Document
2018-08-30 6-K EC APPROVES BYDUREON BCISE DEVICE FOR T2 DIABETES View Document
2018-08-23 CERT NYSE CERTIFICATION - ASTRAZENECA PLC View Document
2018-08-23 6-K ASTRAZENECA PIIIB TRIAL UPDATE FOR BEVESPI IN COPDASTRAZENECA PIIIB TRIAL UPDATE View Document
2018-08-21 6-K AZ'S TAGRISSO APPROVED IN JAPAN FOR 1ST-LINE NSCLC View Document
2018-08-17 8-A12B FORM 8-A12B View Document
2018-08-17 6-K FORM 6-K View Document
2018-08-16 424B2 FORM 424B2 View Document
2018-08-15 6-K ASTRAZENECA PRICES A $3BN BOND ISSUE View Document
2018-08-15 FWP FORM FWP View Document
2018-08-14 S-8 S-8 View Document
2018-08-14 FWP FORM FWP View Document
2018-08-14 424B2 FORM 424B2 View Document
2018-08-10 6-K 6-K View Document
2018-08-03 6-K EMA GRANTS OD FOR SELUMETINIB IN NF1 View Document
2018-08-01 6-K TOTAL VOTING RIGHTS View Document
2018-07-27 6-K CHMP RECOMMENDS IMFINZI FOR STAGE III NSCLC View Document
2018-07-26 6-K 6-K View Document
2018-07-24 6-K ATACAND TO BE DIVESTED TO CHEPLAPHARM IN EUROPE View Document
2018-07-18 6-K HOLDING(S) IN COMPANY View Document
2018-07-02 6-K TOTAL VOTING RIGHTS View Document
2018-07-02 6-K LYNPARZA APPROVED IN JAPAN FOR BRCAM BREAST CANCER View Document
2018-07-02 6-K IMFINZI APPROVED IN JAPAN FOR STAGE III NSCLC View Document
2018-06-29 11-K View Document
2018-06-29 6-K BYDUREON RECEIVES POSITIVE CHMP OPINION FOR BCISE View Document
2018-06-28 6-K AZ AND LUYE PHARMA COMPLETE AGREEMENT FOR SEROQUEL View Document
2018-06-27 6-K LYNPARZA: SIGNIFICANT PFS 1ST-LINE OVARIAN CANCER View Document
2018-06-26 6-K BOARD COMMITTEE CHANGES View Document
2018-06-22 6-K PUBLICATION OF A PROSPECTUS View Document
2018-06-12 6-K UPDATE: LANABECESTAT PHASE III ALZHEIMER'S TRIALS View Document
2018-06-08 6-K EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC View Document
2018-06-08 6-K DIRECTOR DECLARATION View Document
2018-06-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2018-06-01 6-K TOTAL VOTING RIGHTS View Document
2018-06-01 6-K DIRECTOR DECLARATION View Document
2018-05-30 6-K UPDATE ON TERRANOVA PIII TRIAL FOR FASENRA IN COPD View Document
2018-05-25 6-K AZS IMFINZI: SIGNIFICANT OS IN STAGE III NSCLC View Document
2018-05-21 6-K AZ REGULATORY SUBMISSION IN JAPAN FOR FORXIGA View Document
2018-05-21 6-K US FDA APPROVES LOKELMA FOR ADULT HYPERKALAEMIA View Document
2018-05-18 6-K RESULT OF AGM View Document
2018-05-18 6-K AZN: Q1 2018 RESULTS View Document
2018-05-11 6-K ASTRAZENECA UPDATE ON FASENRA PIII TRIAL IN COPD View Document
2018-05-08 6-K EMA APPROVES LYNPARZA: MAINTENANCE OVARIAN CANCER View Document
2018-05-07 6-K AZ AND LUYE PHARMA ENTER AGREEMENT FOR SEROQUEL View Document
2018-05-04 6-K DIRECTOR DECLARATION View Document
2018-05-01 6-K TOTAL VOTING RIGHTS View Document
2018-04-27 6-K AZ: POSITIVE CHMP FOR TAGRISSO FIRST-LINE NSCLC View Document
2018-04-24 6-K ASTRAZENECA:HIGH LEVEL RESULTS OF THE ARCTIC TRIAL View Document
2018-04-19 6-K FDA APPROVES TAGRISSO FOR 1ST-LINE USE IN NSCLC View Document
2018-04-13 6-K 6-K View Document
2018-04-13 6-K NOTICE OF AGM View Document
2018-04-05 6-K DIRECTORATE CHANGE View Document
2018-04-03 6-K TOTAL VOTING RIGHTS View Document
2018-04-03 6-K FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA View Document
2018-04-03 6-K AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU View Document
2018-03-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2018-03-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2018-03-22 6-K LOKELMA APPROVED IN THE EU View Document
2018-03-12 6-K ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE View Document
2018-03-07 6-K FILING OF FORM 20-F WITH SEC View Document
2018-03-06 IRANNOTICE IRANNOTICE View Document
2018-03-06 20-F 20-F View Document
2018-03-06 6-K ANNUAL FINANCIAL REPORT View Document
2018-03-01 6-K TOTAL VOTING RIGHTS View Document
2018-02-23 6-K LYNPARZA CHMP FOR OVARIAN CANCER MAINTAINANCE View Document
2018-02-20 6-K ASTRAZENECA'S IMFINZI APPROVED FOR STAGE III NSCLC View Document
2018-02-15 6-K SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS View Document
2018-02-08 SC 13G SCHEDULE 13G View Document
2018-02-08 SC 13G/A SEC SCHEDULE 13G View Document
2018-02-05 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2018-02-02 6-K AZN: FULL-YEAR 2017 RESULTS View Document
2018-02-01 6-K TOTAL VOTING RIGHTS View Document
2018-01-30 SC 13G/A View Document
2018-01-26 6-K/A AZ REPORTS PHASE III RESULTS FOR PT010 IN COPD View Document
2018-01-26 6-K AZ REPORTS PHASE III RESULTS FOR PT010 IN COPD View Document
2018-01-19 6-K ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN View Document
2018-01-19 6-K LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER View Document
2018-01-12 6-K FDA APPROVES LYNPARZA FOR METASTATIC BREAST CANCER View Document
2018-01-10 6-K ASTRAZENECA'S FASENRA APPROVED IN THE EU View Document
2018-01-02 6-K TOTAL VOTING RIGHTS View Document
2017-12-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2017-12-18 6-K FDA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC View Document
2017-12-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2017-12-11 SC 13D/A SC 13D/A View Document
2017-12-05 4 FORM 4 SUBMISSION View Document
2017-12-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2017-12-01 6-K TOTAL VOTING RIGHTS View Document
2017-11-28 6-K EMA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC View Document
2017-11-27 6-K AZ SUBMITS TAGRISSO IN JAPAN FOR 1ST-LINE NSCLC View Document
2017-11-15 6-K AZ FASENRA RECEIVES FDA APPROVAL FOR SEVERE ASTHMA View Document
2017-11-13 6-K BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA View Document
2017-11-09 6-K AZN: YEAR-TO-DATE AND Q3 2017 RESULTS ANNOUNCEMENT View Document
2017-11-01 6-K TOTAL VOTING RIGHTS View Document
2017-11-01 6-K ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL View Document
2017-11-01 6-K ASTRAZENECA TRALOKINUMAB UPDATE IN SEVERE ASTHMA View Document
2017-10-31 6-K US FDA APPROVES ASTRAZENECA'S CALQUENCE FOR MCL View Document
2017-10-23 6-K US FDA APPROVES BYDUREON BCISE FOR TYPE-2 DIABETES View Document
2017-10-23 6-K AZ AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN View Document
2017-10-18 6-K FDA PRIORITY REVIEW FOR LYNPARZA IN BREAST CANCER View Document
2017-10-17 6-K FDA ACCEPTS SBLA FILE FOR IMFINZI; PRIORITY REVIEW View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.



We can also help with your taxes.

Formal Tax

www.formal.tax





(402) 804-8293


Formal Financial App
Google Play - Apple Store

created using: Admin Canvas